Gossamer Bio Inc To Discuss Seralutinib Program Update Call Transcript

Jul 25, 2023 / 02:00PM GMT
Bryan Giraudo - Gossamer Bio, Inc. - COO & CFO

Good morning, everyone. Thank you for joining us for our Seralutinib Program update discussion about PROSERA's Phase III design and interim TORREY results. It's Bryan Giraudo with Gossamer Bio. Next slide, please. Wanted everyone to remember the -- our forward-looking statements that the comments we'll be making today will be contained in our SEC public disclosures and the rest, but also know that we are making forward-looking statements about the future of the PROSERA study at Gossamer, and those can be only relied on for a period of time.

With that said, let me turn it over to Chief Executive Officer, Chairman and Founder, Faheem Hasnain to kick off our presentation. Faheem?

Faheem Hasnain - Gossamer Bio, Inc. - Co-Founder, CEO, President & Chairman

Yes. Thanks, Bryan, and thanks to all of you for joining us on this call. Along with myself and Bryan today, we have other people from Gossamer, Richard Aranda, who's our Chief Medical Officer; Rob Roscigno, VP Clinical Development. He heads up

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot